Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide CME for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca
This activity aims to update oncology nurses and other oncology healthcare professionals who participate in the multidisciplinary treatment of patients with lung cancer by updating these practitioners on key data sets, educating them on how this evidence can be interpreted in the context of evolving treatment paradigms, and providing expert guidance on how to proactively mitigate and manage treatment-related toxicities in multiple lines of care in lung cancer treatment.
Based on the historically specialist attendance of the ONS Annual Meeting, PER® recognizes that an educational design must be unique at the ONS Annual Meeting to attract and engage an oncology nurse with a very high baseline knowledge. The interactive nature of the highly clinical Working Group educational format will encourage the sharing of best practices and foster collaboration among the multidisciplinary faculty and advanced and expert participants. Extensive Q&A sessions will allow the audience to discuss cases and scenarios from their own practices, thereby increasing engagement and enhancing learning. This format was successfully utilized in the 2016 activity, and it is proposed that it continue. The activity co-chairs are excited for this educational design and have provided in-depth guidance to maximize scheduling and topics to foster interaction and maximum impact.
The ability to target specific mutations in lung cancer now allows for personalized treatment options in multiple lines of care for patients with EGFR-mutated and ALK-rearranged lung cancers. Indeed, tyrosine kinase inhibitors have demonstrated improved outcomes for patients with advanced forms of these tumors in frontline and relapsed settings. Drug resistance ultimately occurs following frontline use of EGFR-targeted therapy, either intrinsically (suboptimal response at the outset of therapy) or acquired (disease progression following initial partial or complete response). Decisions regarding what constitutes progression, when to rebiopsy and retest for molecular markers, how those tests can be best facilitated and communicated, and when to switch to another agent are key to managing these patients. Just as important to optimizing outcomes is attention to mitigating and managing predictable treatment-related toxicities, another manner by which care can be personalized for the individual patient with lung cancer. Educational activities that provide practitioners with the opportunity to engage with experts on real-world case scenarios and compare their answers with those authorities and their peers provides valuable insight into their own practices.
The fast pace of developments in the management of EGFR-targeted lung cancers has challenged practitioners to maintain state-of-the-art practices with regard to monitoring for adverse events and discussing the efficacy of targeted strategies with their patients. Advances in the field will continue to emerge in 2017, and these will create knowledge and/or practice gaps for oncology-focused nurses who strive to optimize care for their patients.
Given the importance of interprofessional strategies in the management of lung cancers, it is important that educational activities are similarly developed in a multidisciplinary manner. This underlies why PER® recommends the multidisciplinary Working Group format that allows nurses who manage lung cancers to work with their peers to optimize outcomes and bridge practice gaps related to new targeted strategies, apply approaches to their care settings, and consider the potential impact that new data or ongoing trials may have in the field of lung cancer management.
Upon completion of this activity, participants will be better prepared to to:
- Explain current and emerging testing platforms in the context of emerging methods to overcome barriers associated with tumor biopsies in the field of lung cancer treatment
- Detail key counseling points to address with patients with lung cancer who are awaiting results from tumor tissue testing
- Describe current and emerging evidence concerning the use of EGFR-targeted strategies in frontline and relapsed advanced non–small cell lung cancer (NSCLC) disease settings
- Apply best nursing practices to counsel patents with advanced NSCLC concerning the prevention, mitigation, and management of treatment-related toxicities
This educational activity is directed toward all attendees of the 42nd ONS Annual Congress, including nurses and other healthcare professionals with an interest in the treatment of lung cancers.
Karen C. Lee, MSN, FNP-BC
Thoracic Oncology Program
Mount Sinai Health System
New York, NY
Benjamin P. Levy, MD
Assistant Professor, Icahn School of Medicine
Medical Director, Thoracic Oncology Program
Mount Sinai Health System
Associate Director, Cancer Clinical Trials Office
Mount Sinai Hospital
New York, NY